No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
94 |
4. Check minimum number of eventsNone |
94 |
5. Include endpoints |
113 |
6. Filter based on genotype QC (FinnGen only) |
113 |
Control definitions (FinnGen only)
- Control exclude
- E4_OBESITY_HYPER
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Other hyperalimentation
based on the number of shared cases.
Similar with more cases:
- Obesity and other hyperalimentation
- Endocrine, nutritional and metabolic diseases
- Any event in hilmo or specialist outpatient
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 767 | 460 | 298 |
| Only index persons | 615 | 384 | 231 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 49.68 | 48.81 | 50.63 |
| Only index persons | 48.07 | 47.96 | 48.24 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 113 | 74 | 39 |
| Unadjusted period prevalence (%) | 0.02 | 0.03 | 0.02 |
| Median age at first event (years) | 50.61 | 47.99 | 55.57 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 107
- Matched controls
- 1071
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E68
ICD-10 Finland
Sequelae of hyperalimentation
+∞
68.2
58
*
E66.8
ICD-10 Finland
Other obesity
225.2
32.7
32
*
E66.01
ICD-10 Finland
Obesity due to excess calories
46.8
27.6
33
10
E66.00
ICD-10 Finland
Metabolic syndrome
91.2
20.6
22
*
E66.9
ICD-10 Finland
Obesity, unspecified
71.3
16.3
18
*
QBJ30
NOMESCO Finland
Correction of abdominal apron
+∞
16.0
15
*
E67.3
ICD-10 Finland
Hypervitaminosis D
+∞
11.7
11
*
JDF11
NOMESCO Finland
Laparoscopic gastric bypass
+∞
10.6
10
*
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
24.4
9.6
13
6
T82
ICPC
Obesity
15.6
9.5
15
11
E66.2
ICD-10 Finland
Extreme obesity with alveolar hypoventilation
+∞
9.5
9
*
E67.8
ICD-10 Finland
Other specified hyperalimentation
+∞
9.5
9
*
103
Kela drug reimbursment
Diabetes, insulin-treated
4.1
9.2
43
152
27899
ICD-8 Finland
Other hyperalimentation, Other and unspecified
+∞
8.4
8
*
27799
ICD-8 Finland
Obesity not specified as of endocrine origin
+∞
8.4
8
*
E67.2
ICD-10 Finland
Megavitamin-B6syndrome
+∞
8.4
8
*
G47.3
ICD-10 Finland
Sleep apnoea
4.4
8.0
31
91
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
3.8
7.7
37
131
A10BA02
ATC
metformin; oral
3.6
7.6
42
164
SPAT1262
SPAT
Handing over of treatment supplies
4.0
7.1
30
95
215
Kela drug reimbursment
Diabetes, non-insulin-treated
3.5
6.9
36
135
JKA21
NOMESCO Finland
Laparoscopic cholecystectomy
5.0
6.8
22
53
Z3231
NOMESCO Finland
Registered nurse
3.4
6.7
38
150
285
Kela drug reimbursment
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
16.2
6.0
9
6
Mortality – FinRegistry
↥Association
Association between endpoint E4_HYPERALI and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_HYPERALI | 2.001 [1.3, 3.08] | 0.002 |
| Birth year | 0.997 [0.99, 1.01] | 0.458 |
During the follow-up period (1.1.1998 — 31.12.2019), 64 out of 272 females with E4_HYPERALI died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_HYPERALI | 3.536 [2.12, 5.89] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.011 |
During the follow-up period (1.1.1998 — 31.12.2019), 65 out of 172 males with E4_HYPERALI died.
Mortality risk
Mortality risk for people of age
years, who have E4_HYPERALI.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.189% | 0.859% |
| 5 | 1.144% | 4.315% |
| 10 | 3.079% | 10.302% |
| 15 | 5.724% | 18.891% |
| 20 | 9.954% | 29.966% |
Relationships between endpoints
↥Index endpoint: E4_HYPERALI – Other hyperalimentation
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
Extremity
rg [CI]
Extremity
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data